RC-3095

• CAT Number: I008988
• CAS Number: 138147-78-1
• Molecular Formula: C56H79N15O9
• Molecular Weight: 1106.32
• Purity: ≥95%
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C56H79N15O9/c1-29(2)18-35(25-61-42(50(58)74)19-30(3)4)66-55(79)45(21-34-24-59-28-64-34)68-48(73)27-63-56(80)49(31(5)6)71-51(75)32(7)65-54(78)44(20-33-23-60-39-14-10-8-12-36(33)39)70-52(76)41(16-17-47(57)72)69-53(77)43-22-38-37-13-9-11-15-40(37)67
• InChIKey: IUYCRRDHLJIJBB-QAGBKCHLSA-N
• SMILES: O=C(N[C@H](C(N[C@@H](C)C(N[C@@H](C(C)C)C(NCC(N[C@@H](CC1=CN=CN1)C(N[C@@H](CC(C)C)CN[C@H](C(N)=O)CC(C)C)=O)=O)=O)=O)=O)CC2=CNC3=C2C=CC=C3)[C@@H](NC([C@H]4CC5=C(CN4)NC6=C5C=CC=C6)=O)CCC(N)=O

RC-3095 (Cat.No:I008988) is a gastrin-releasing peptide receptor antagonist,synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo. RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. RC3095 inhibits tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.

Reference

1:RC-3095, a selective gastrin-releasing peptide receptor antagonist, does not protect the lungs in an experimental model of lung ischemia-reperfusion injury. Oliveira-Freitas VL, Thomaz LD, Simoneti LE, Malfitano C, De Angelis K, Ulbrich JM, Schwartsmann G, Andrade CF.Biomed Res Int. 2015;2015:496378. doi: 10.1155/2015/496378. Epub 2015 Mar 29. PMID: 25893195 Free PMC Article2:RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo. Hong SK, Yang SY, Yin SH, Yang KX.Pancreas. 2014 Jan;43(1):15-21. doi: 10.1097/MPA.0b013e3182a714cf. PMID: 24326363 3:Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Oliveira PG, Grespan R, Pinto LG, Meurer L, Brenol JC, Roesler R, Schwartsmann G, Cunha FQ, Xavier RM.Arthritis Rheum. 2011 Oct;63(10):2956-65. doi: 10.1002/art.30486. PMID: 21953084 Free Article4:Effects of intracerebral ventricular administration of gastrin-releasing peptide and its receptor antagonist RC-3095 on learned fear responses in the rat. Merali Z, Mountney C, Kent P, Anisman H.Behav Brain Res. 2011 Jan 20;216(2):519-24. doi: 10.1016/j.bbr.2010.08.027. Epub 2010 Aug 27. PMID: 20801162 5:Effects of N-acetylcysteine/deferoxamine, taurine and RC-3095 on respiratory chain complexes and creatine kinase activities in rat brain after sepsis. Cassol OJ Jr, Rezin GT, Petronilho FC, Scaini G, Gonçalves CL, Ferreira GK, Roesler R, Schwartsmann G, Dal-Pizzol F, Streck EL.Neurochem Res. 2010 Apr;35(4):515-21. doi: 10.1007/s11064-009-0089-3. PMID: 20238483 6:Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095). Sotomayor S, Muñoz-Moreno L, Carmena MJ, Schally AV, Sánchez-Chapado M, Prieto JC, Bajo AM.Int J Cancer. 2010 Oct 15;127(8):1813-22. doi: 10.1002/ijc.25192. PMID: 20099275 Free Article7:Effects of the gastrin-releasing peptide antagonist RC-3095 in a rat model of ulcerative colitis. Damin DC, Santos FS, Heck R, Rosito MA, Meurer L, Kliemann LM, Roesler R, Schwartsmann G.Dig Dis Sci. 2010 Aug;55(8):2203-10. doi: 10.1007/s10620-009-1032-9. Epub 2009 Nov 6. PMID: 19894117 8:Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. de Oliveira MS, Cechim G, Braganhol E, Santos DG, Meurer L, de Castro CG Jr, Brunetto AL, Schwartsmann G, Battastini AM, Lenz G, Roesler R.J Neurooncol. 2009 Jun;93(2):191-201. doi: 10.1007/s11060-008-9775-2. Epub 2009 Jan 8. Erratum in: J Neurooncol. 2009 Jun;93(2):203. Schwarstmann, Gilberto [corrected to Schwartsmann, Gilberto]. PMID: 19129973 9:Opposite effects of low and high doses of the gastrin-releasing peptide receptor antagonist RC-3095 on memory consolidation in the hippocampus: possible involvement of the GABAergic system. Dantas Ados S, Luft T, Henriques JA, Schwartsmann G, Roesler R.Peptides. 2006 Sep;27(9):2307-12. Epub 2006 May 2. PMID: 16650508 10:Non-associative learning and anxiety in rats treated with a single systemic administration of the gastrin-releasing peptide receptor antagonist RC-3095. Martins MR, Reinke A, Valvassori SS, Machado RA, Quevedo J, Schwartsmann G, Roesler R.Peptides. 2005 Dec;26(12):2525-9. Epub 2005 Jul 14. PMID: 16023260